Evidence map›Paper›PMID 39496877›Full record

ArticleMolecular neurobiology2025

Dexmedetomidine Improves Long-term Neurological Outcomes by Promoting Oligodendrocyte Genesis and Myelination in Neonatal Rats Following Hypoxic-ischemic Brain Injury.

Hang Xue, Zixuan Ding, Xiaoyan Chen, Xu Yang, Yufei Jia, Ping Zhao, Ziyi Wu

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Hang XueDepartment of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Zixuan DingDepartment of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Xiaoyan ChenDepartment of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Xu YangDepartment of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Yufei JiaDepartment of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Ping ZhaoDepartment of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Ziyi WuDepartment of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, 110004, China. wuzy@sj-hospital.org.

Funding

Applied Basic Research Program of Liaoning Province No.2022JH2/101500055 to Hang Xue and No. 2022JH2/101500056 to Ziyi Wuthe National Natural Science Foundation of China No.82071215 to Ping Zhao
6 · The paper itself

Abstract

Neonatal hypoxic-ischemic brain injury (HIBI) can lead to white matter damage, which significantly contributes to cognitive dysfunction, emotional disorders, and sensorimotor impairments. Although dexmedetomidine enhances neurobehavioral outcomes, its impact on oligodendrocyte genesis and myelination following hypoxic-ischemic events, as well as the underlying mechanisms, remain poorly understood. Dexmedetomidine was administered 15 min post-HIBI. We assessed neurobehavioral deficits using various tests: surface righting, negative geotaxis, forelimb grip strength, cliff avoidance, sensory reflexes, novel object recognition, T-maze, and three-chamber social interaction. We also investigated the relationship between myelination and neurobehavioral outcomes. Measurements included oligodendrocyte precursor cell (OPC) proliferation and survival 24 h post-injury, early myelination, and oligodendrocyte differentiation by postnatal day 14. Furthermore, we evaluated microglial activation towards the M2 phenotype and the extent of neuroinflammation during the acute phase. Dexmedetomidine significantly ameliorated long-term neurological deficits caused by HIBI. Pearson linear regression analysis revealed a strong correlation between long-term neurological outcomes and myelin maturity. The treatment notably mitigated the long-term deterioration of myelin formation and maturation following HIBI. This protective effect was primarily due to enhanced OPC proliferation and survival post-HIBI during the acute phase and, to a lesser extent, to the modulation of microglial activity towards the M2 phenotype and a reduction in neuroinflammation. Dexmedetomidine offers substantial protection against long-term neurobehavioral disabilities induced by HIBI, primarily by revitalizing the impaired survival and maturation of oligodendrocyte progenitor cells and promoting myelination.

Indexed as

DexmedetomidineHypoxia-Ischemia, BrainMyelin SheathOligodendrogliaAnimalsAnimals, NewbornBehavior, AnimalCell DifferentiationCell ProliferationMaleMicrogliaRatsRats, Sprague-DawleyDexmedetomidineDexmedetomidineHypoxic ischemia brain injuryMyelinationOligodendrocyte

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.